1. Medtech Insight
  2. >>Policy & Regulation

Industry Groups Push CMS To Pay For Algorithms In Multi-Analyte Tests

The agency’s proposal not to separately pay for the algorithmic analysis that forms the basis of many multi-analyte molecular diagnostic tests misconstrues the nature of the tests, industry groups argue. They call for a final determination by CMS that more truly reflects the value of these assays.

CMS’ proposal not to establish payments for newly created codes for multi-analyte assays that rely on algorithmic analysis is attracting a strong rebuke from diagnostic industry and lab stakeholders.

AdvaMedDx, the American Clinical Laboratory Association (ACLA) and Biotechnology Industry Organization (BIO) each pressed CMS in recent comments to withdraw...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

Brazil’s Medtechs Cheered By US Tariff Safety Net And Market Diversity Drive

 
• By Bernard Murphy

Brazil’s government has implemented a three-pronged strategy to protect local industry, including medtech, from the worst effects of the 50% US tariff on Brazilian exports. But the option of counter-tariffs has not gone away.

Real-World Evidence Can Help Overcome Regulatory and Market Barriers for Pediatric Medical Devices

 
• By Elizabeth Orr

At AdvaMed’s MedTech Conference in San Diego, speakers brainstorm ways to bring devices to treat children to market more quickly through creative collaboration, better use of real-world data, and taking advantage of ‘low-hanging fruit’ like expanded size ranges.

AdvaMed Warns Of Challenges With Remote Devices While Noting Their Potential

 
• By Brian Bossetta

Though the advance of remote medical device technology allows for better at-home care, it comes with challenges and risks, says AdvaMed, which has published a safety bulletin guiding stakeholders on the operation of remote devices.

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 
• By Amanda Maxwell

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

More from Medtech Insight

AdvaMed Warns Of Challenges With Remote Devices While Noting Their Potential

 
• By Brian Bossetta

Though the advance of remote medical device technology allows for better at-home care, it comes with challenges and risks, says AdvaMed, which has published a safety bulletin guiding stakeholders on the operation of remote devices.

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 
• By Amanda Maxwell

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By Marion Webb

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.